ArticleHeart and vessels2026
Prognostic implications of a four-group classification based on estimated plasma volume status and creatinine in acute heart failure.
Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In response to "Letter to the editor regarding "Aortic calcification and contrast-associated acute kidney injury in patients undergoing urgent coronary angiography"".Heart and vessels · 2026Article
- Aortic calcification and CA-AKI: clarifying diagnostic performance and clinical utility.Heart and vessels · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the prognostic value of a four-group classification combining estimated plasma volume status (ePVS) and serum creatinine (Cre) in patients hospitalized for acute decompensated heart failure (ADHF). We analyzed 914 patients from the SAKURA HF Registry-2 enrolled between September 2018 and December 2023. At discharge, patients were stratified into four groups using ePVS (cutoff, 5.5 mL/g) and Cre (cutoff, 1.1 mg/dL): low-ePVS/low-Cre (n = 285), high-ePVS/low-Cre (n = 136), low-ePVS/high-Cre (n = 263), and high-ePVS/high-Cre (n = 230). The primary endpoint was a composite of all-cause mortality or heart failure rehospitalization. Multivariable Cox models were adjusted for clinical, laboratory, echocardiographic, and discharge-medication covariates. Median age was 74 years and 68% were men. Over a median follow-up of 368 days (interquartile range [IQR], 89-548), 349 patients (38.2%) experienced the primary endpoint, with significant differences among groups (log-rank p < 0.001). In multivariable models, compared with low-ePVS/low-Cre, risk was higher in high-ePVS/low-Cre (hazard ratio [HR] 2.38, 95% confidence interval [CI] 1.31-4.30; p = 0.004) and high-ePVS/high-Cre (HR 1.98, 95% CI 1.12-3.48; p = 0.018), but not in low-ePVS/high-Cre (HR 1.62, 95% CI 0.94-2.79; p = 0.08). A discharge-based ePVS-Cre classification provided clinically relevant risk stratification after ADHF. Elevated ePVS despite non-elevated serum creatinine independently predicted adverse outcomes. When ePVS was low, the excess risk associated with elevated creatinine was attenuated after adjustment, whereas concomitant elevation of ePVS and creatinine remained a high-risk category. This simple bedside framework may support discharge risk assessment.
Indexed as
Identifiers
42618668What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.